64|184|Public
25|$|In January 2009, {{the largest}} <b>criminal</b> <b>fine</b> in U.S. history, totaling $1.415 billion was imposed on Lilly for illegal {{marketing}} of its best-selling product, the atypical antipsychotic medication, Zyprexa.|$|E
25|$|In Southern Union Co. v. United States, the Supreme Court {{determined}} {{that when a}} <b>criminal</b> <b>fine</b> is sufficient to trigger the Sixth Amendment jury-trial guarantee, facts that would increase the penalty beyond the statutory maximum must be submitted to a jury and proved beyond a reasonable doubt.|$|E
25|$|In September 2009, Pfizer {{agreed to}} pay $2.3billion to settle civil and {{criminal}} allegations that it had illegally marketed four drugsBextra, Geodon, Zyvox, and Lyricafor non-approved uses; it was Pfizer's fourth such settlement in a decade. The payment included $1.3 billion in criminal penalties for felony violations of the Food, Drug and Cosmetic Act, and $1 billion to settle allegations it had illegally promoted the drugs for uses that were not approved by the U.S. Food and Drug Administration (FDA) and caused false claims to be submitted to Federal and State programs. The <b>criminal</b> <b>fine</b> was the largest ever assessed in the United States up to that time. Pfizer has entered an extensive corporate integrity agreement (CIA) with the Office of Inspector General and {{will be required to}} make substantial structural reforms within the company, and maintain the Pfizer website (www.pfizer.com/pmc) to track the company's post marketing commitments. Pfizer had to also put a searchable database of all payments to physicians the company had made on the Pfizer website by March 31, 2010.|$|E
50|$|Because those prosecuted {{and convicted}} under H.R. 258 could {{be subject to}} civil and <b>criminal</b> <b>fines,</b> the federal {{government}} might collect additional fines if the legislation is enacted. Civil and <b>criminal</b> <b>fines</b> are recorded as revenues. <b>Criminal</b> <b>fines</b> are deposited in the Crime Victims Fund and later spent. CBO expects that any additional revenues and direct spending would not be significant because relatively few cases would likely be affected.|$|R
40|$|Writing {{a thesis}} {{with the title}} “financial income {{countries}} which sourced from the enforcement of <b>criminal</b> <b>fines</b> in 2008 in th jurisdiction in Bantul district courts” has several aims. First, to describing the legal regulation of <b>criminal</b> <b>fines</b> and prison instead. Second, explain and evaluate the country’s financial income through {{the decision of the}} <b>criminal</b> <b>fines</b> imposed by courts Bantul during the year 2008, and the last to suggesting legal regulation on the enforcement of <b>criminal</b> <b>fines</b> as a possible constituendum ius or that should be applied so, it can be contribute to the country’s financial income. This research is a legal research and including a study of the formation of positive of law. Data in this research using library data or studies that document was processed by disistematisir. Then described and evaluated for further regulation should be determined how the law of <b>criminal</b> <b>fines</b> in Indonesia in order to contribute to the country’s financial income. Based on the results of this research from the author, <b>criminal</b> <b>fines</b> imposed by the Bantul district courts during 2008 was not effective because the prisoners are more likely to choose to undergo a replacement prison. That is because the provisions of article 30 of the Criminal Code (KUHP) that actually inhibit the effectiveness of <b>criminal</b> <b>fines</b> itself must be changed. It also needs to confiscate the execution of established institutions that substitute prison is really ultimum remidium...|$|R
5000|$|Nondeductibility of {{payments}} considered {{in violation of}} public policy, such as <b>criminal</b> <b>fines</b> ...|$|R
500|$|In Ex parte Watkins (1830), the Court {{held that}} the writ did not lie after a federal {{criminal}} conviction even if the indictment failed to state an offense. [...] Three years later, with the same petitioner, in Ex parte Watkins (1833), the Court did issue the writ because the petitioner was detained beyond his authorized sentence for non-payment of a fine; although the Court held that such detention would be permissible under the writ of capias pro fine (generally, a writ ordering the imprisonment of a defendant until a <b>criminal</b> <b>fine</b> is paid), [...] it held {{that it was not}} under the writ of capias ad satisfaciendum (a civil law analog). After further proceedings in the D.C. circuit court, Watkins was discharged.|$|E
2500|$|In 2009, four {{sales representatives}} for Eli Lilly filed {{separate}} qui tam lawsuits {{against the company}} for illegally marketing the drug Zyprexa for uses not approved by the Food and Drug Administration. Eli Lilly pleaded guilty to actively promoting Zyprexa for off-label uses, particularly {{for the treatment of}} dementia in the elderly. The $1.415 billion penalty included an $800 million civil settlement and a $515 million <b>criminal</b> <b>fine.</b> The U.S. Justice Department said the <b>criminal</b> <b>fine</b> of $515 million was the largest ever in a health care case, and the largest <b>criminal</b> <b>fine</b> for an individual corporation ever imposed in a U.S. criminal prosecution of any kind. [...] "That was a blemish for us," [...] John C. Lechleiter, CEO of Lilly, told The New York Times. [...] "We don’t ever want that to happen again. We put measures in place to assure that not only do we have the right intentions in integrity and compliance, but we have systems in place to support that." [...] In an internal email, Lechleiter had stated [...] "we must seize the opportunity to expand our work with Zyprexa in this same child-adolescent population" [...] (for off-label use.) ...|$|E
2500|$|GSK {{pleaded guilty}} in 2012 and paid a $3billion settlement, {{including}} a <b>criminal</b> <b>fine</b> of $1billion. The fine included an amount for [...] "preparing, publishing and distributing a misleading medical journal article that misreported that a clinical trial of Paxil demonstrated efficacy {{in the treatment of}} depression in patients under age 18, when the study failed to demonstrate efficacy".|$|E
50|$|Because those prosecuted {{and convicted}} under H.R. 3627 could {{be subject to}} <b>criminal</b> <b>fines,</b> the federal {{government}} might collect additional fines if the legislation is enacted. <b>Criminal</b> <b>fines</b> are recorded as revenues, deposited in the Crime Victims Fund, and later spent. The CBO expects that any additional revenues and direct spending would not be significant {{because of the small}} number of cases likely to be affected.|$|R
40|$|The Act {{increases}} the fee for filing real and personal property instruments and adds a surcharge to <b>criminal</b> <b>fines.</b> The five-percent penalty added to <b>criminal</b> <b>fines</b> {{is used to}} fund approved victim assistance programs. Additionally, the Act imposes a five-dollar filing fee for any documents pertaining to real property to fund a study of an online computer index of real and personal property records for statewide use...|$|R
50|$|Because those prosecuted {{and convicted}} under H.R. 4771 could {{be subject to}} civil and <b>criminal</b> <b>fines,</b> the federal {{government}} might collect additional fines if the legislation is enacted. Civil fines are recorded as revenues. <b>Criminal</b> <b>fines</b> are recorded as revenues, deposited in the Crime Victims Fund, and later spent. CBO expects that any additional revenues and direct spending would not be significant {{because of the small}} number of additional cases likely to be affected.|$|R
2500|$|In March 1990, Raytheon {{pleaded guilty}} to one felony count of {{illegally}} obtaining classified Air Force budget and planning documents. U.S. District Judge Albert V. Bryan, Jr. imposed a $10,000 <b>criminal</b> <b>fine</b> for one felony count of [...] "conveyance without authority" [...] and $900,000 in civil penalties and damages. The documents allegedly gave Raytheon an unfair advantage against its competitors in bidding for weapons contracts. Although the plea only involved 1983 Air Force documents, United States Attorney Henry Hudson said Raytheon also illegally obtained {{a wide range of}} secret Pentagon documents.|$|E
5000|$|In September 2009 Bextra was at {{the center}} of the [...] "largest health care fraud {{settlement}} and the largest <b>criminal</b> <b>fine</b> of any kind ever." [...] Pfizer paid a $2.3 billion civil and <b>criminal</b> <b>fine.</b> Pharmacia and Upjohn, a Pfizer subsidiary, violated the United States Food, Drug and Cosmetic Act for misbranding Bextra [...] "with the intent to defraud or mislead." ...|$|E
5000|$|Petty {{offences}} (contraventions), {{punishable by}} <b>criminal</b> <b>fine</b> up to [...] € ( [...] € for recidivists).|$|E
25|$|The maximum {{prison term}} is 6 {{months for the}} first offense and 2 years for any {{subsequent}} offense. In addition to the above <b>criminal</b> <b>fines</b> and penalties, civil fines may also be imposed.|$|R
5000|$|... {{is amended}} {{to provide for}} <b>criminal</b> <b>fines</b> to be the greater of $5,000,000 or three times the trade secret's value (including any {{reproduction}} costs that the holder of the trade secret has avoided).|$|R
50|$|The maximum {{prison term}} is 6 {{months for the}} first offense and 2 years for any {{subsequent}} offense. In addition to the above <b>criminal</b> <b>fines</b> and penalties, civil fines may also be imposed.|$|R
50|$|In January 2009, {{the largest}} <b>criminal</b> <b>fine</b> in U.S. history, totaling $1.415 billion was imposed on Lilly for illegal {{marketing}} of its best-selling product, the atypical antipsychotic medication, Zyprexa.|$|E
50|$|In March 2012, Biomet Inc. paid a <b>criminal</b> <b>fine</b> of US$17.3 {{million to}} resolve charges of FCPA {{violations}} and US$5.5 million in disgorgement of profits and pre-judgment {{interest to the}} SEC.|$|E
50|$|In June 2015, the Delaware Legislature {{passed and}} Gov. Jack Markell {{signed a bill}} to reduce the penalty for {{possession}} of up to an ounce of marijuana to a simple fine. MPP led the two-year lobbying effort for the law, which reduces the penalty for possession of up to an ounce of marijuana to a civil fine for adults 21 and older. Minors {{under the age of}} 18 will be subject to a $100 <b>criminal</b> <b>fine,</b> while those between 18 and 21 will be subject to a $100 civil fine for a first offense and a $100 <b>criminal</b> <b>fine</b> for a second offense.|$|E
50|$|In 2008 in the US, LG Display Co., Chunghwa Picture Tubes and Sharp Corp., {{agreed to}} plead guilty and pay $585 million in <b>criminal</b> <b>fines</b> for conspiring to fix prices of liquid crystal display panels.|$|R
50|$|In 1999 {{the firm}} {{pleaded guilty to}} {{participation}} in a worldwide conspiracy to raise and fix prices for vitamins sold in the USA and globally. Hoffmann-La Roche paid $500 million in <b>criminal</b> <b>fines</b> to the United States.|$|R
50|$|Justice Scalia wrote a concurring opinion, expressing {{concern about}} the judge also acting as rulemaker and enforcer. Justice Ginsburg also wrote a concurring opinion, joined by Chief Justice Rehnquist, further elucidating the {{distinction}} between civil and <b>criminal</b> <b>fines.</b>|$|R
5000|$|In 2009, four {{sales representatives}} for Eli Lilly filed {{separate}} qui tam lawsuits {{against the company}} for illegally marketing the drug Zyprexa for uses not approved by the Food and Drug Administration. Eli Lilly pleaded guilty to actively promoting Zyprexa for off-label uses, particularly {{for the treatment of}} dementia in the elderly. The $1.415 billion penalty included an $800 million civil settlement and a $515 million <b>criminal</b> <b>fine.</b> The U.S. Justice Department said the <b>criminal</b> <b>fine</b> of $515 million was the largest ever in a health care case, and the largest <b>criminal</b> <b>fine</b> for an individual corporation ever imposed in a U.S. criminal prosecution of any kind. [...] "That was a blemish for us," [...] John C. Lechleiter, CEO of Lilly, told The New York Times. [...] "We don’t ever want that to happen again. We put measures in place to assure that not only do we have the right intentions in integrity and compliance, but we have systems in place to support that." [...] In an internal email, Lechleiter had stated [...] "we must seize the opportunity to expand our work with Zyprexa in this same child-adolescent population" [...] (for off-label use.) ...|$|E
50|$|On June 23, 2008, Samueli {{pleaded guilty}} for lying to SEC for $2.2 billion of backdating. Under the plea bargain, Samueli {{agreed to a}} {{sentence}} of five years probation, a $250,000 <b>criminal</b> <b>fine,</b> and a $12 million payment to the US Treasury.|$|E
50|$|LG Display {{would pay}} $400 million, the second-highest <b>criminal</b> <b>fine</b> that the US Justice Department {{antitrust}} division had ever imposed. Chunghwa would pay $65 million for conspiring with LG Display and other unnamed companies and Sharp would pay $120 million, {{according to the}} department.|$|E
50|$|This {{followed}} the 2008 {{case in the}} US, when LG Display Co., Chunghwa Picture Tubes and Sharp Corp., agreed to plead guilty and pay $585 million in <b>criminal</b> <b>fines</b> for conspiring to fix prices of liquid crystal display panels.|$|R
50|$|Therefore, {{there could}} be no {{compensation}} to the plaintiff as there was no opportunity for the defendant to purge the contempt. Therefore, these were <b>criminal</b> <b>fines,</b> which required appropriate due process - a trial by jury - which had not been afforded.|$|R
5000|$|Illegal {{schemes for}} Serostim: After OCI's Special Agents {{discovered}} {{a conspiracy to}} commit health care fraud by bribing doctors and using other illegal methods to market a treatment for AIDS, the company paid $704 million in <b>criminal</b> <b>fines</b> and restitution to the U.S. Treasury ...|$|R
50|$|In Southern Union Co. v. United States, the Supreme Court {{determined}} {{that when a}} <b>criminal</b> <b>fine</b> is sufficient to trigger the Sixth Amendment jury-trial guarantee, facts that would increase the penalty beyond the statutory maximum must be submitted to a jury and proved beyond a reasonable doubt.|$|E
50|$|South Korea-based LG Display {{would pay}} $400 million, the second-highest <b>criminal</b> <b>fine</b> that the US Justice Department {{antitrust}} division has ever imposed. Chunghwa would pay $65 million for conspiring with LG Display and other unnamed companies and Sharp would pay $120 million, {{according to the}} department.|$|E
5000|$|On April 21, 2017, a US {{federal judge}} ordered Volkswagen [...] "to pay a $2.8 billion <b>criminal</b> <b>fine</b> for rigging {{diesel-powered}} vehicles {{to cheat on}} government emissions tests." [...] The [...] "unprecedented" [...] plea deal formalized a punishment that Volkswagen AG agreed to earlier in 2017.|$|E
5000|$|The act {{also makes}} it illegal to obtain drivers' {{information}} for unlawful purposes or to make false representations to obtain such information. [...] The act establishes <b>criminal</b> <b>fines</b> for noncompliance, and establishes a civil cause of action for drivers against those who unlawfully obtain their information.|$|R
5000|$|In 2014, {{a federal}} appeals court {{overturned}} the 2011 ruling. [...] On April 30, 2015, Kolon Industries settled and agreed to pay $275 million in damages to DuPont. The company also pleaded guilty to a federal charge of conspiracy to convert trade secrets, for which they will pay $85 million in <b>criminal</b> <b>fines.</b>|$|R
5000|$|Publishers, authors, and ISPs may {{be subject}} to arrest, <b>criminal</b> prosecution, <b>fines,</b> and imprisonment.|$|R
